Introgen axes staff as focus shifts to commercialization

Introgen Therapeutics is moving into a new phase of development--which has a reduced focus on R&D. With Advexin p53 newly filed for regulatory review in the U.S. and Europe, Introgen is handing out pink slips to many members of its development staff. The biotech reports that 20 of 70 employees are being axed as the company shifts focus to the regulatory and commercialization process. Introgen applied for FDA approval of Advexin p53 for head and neck cancer, armed with positive mid- and late-stage data. The Texas biotech is asking for a priority review.

- check out the press release
- read the report from the Austin Business Journal

Suggested Articles

A month after scoring $1.6 billion from the U.S. government, Novavax is posting the first human data from its COVID-19 vaccine.

CureVac named a permanent CEO, Franz-Werner Haas, and signed Novartis alum, Igor Splawski, Ph.D. as its new top scientist.

J&J studied the drug in midphase obesity clinical trials, but Merck sees it as a potential treatment for nonalcoholic steatohepatitis.